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Background: SARS-CoV-2 antibody tests are used for population surveillance and might have a future role in
individual risk assessment. Lateral flow immunoassays (LFIAs) can deliver results rapidly and at scale, but
have widely varying accuracy.
Methods: In a laboratory setting, we performed head-to-head comparisons of four LFIAs: the Rapid Test Con-
sortium’s AbC-19TM Rapid Test, OrientGene COVID IgG/IgM Rapid Test Cassette, SureScreen COVID-19 Rapid
Test Cassette, and Biomerica COVID-19 IgG/IgM Rapid Test. We analysed blood samples from 2,847 key work-
ers and 1,995 pre-pandemic blood donors with all four devices.
Findings: We observed a clear trade-off between sensitivity and specificity: the IgG band of the SureScreen
device and the AbC-19TM device had higher specificities but OrientGene and Biomerica higher sensitivities.
Based on analysis of pre-pandemic samples, SureScreen IgG band had the highest specificity (98.9%, 95% con-
fidence interval 98.3 to 99.3%), which translated to the highest positive predictive value across any pre-test
probability: for example, 95.1% (95% uncertainty interval 92.6, 96.8%) at 20% pre-test probability. All four
devices showed higher sensitivity at higher antibody concentrations (“spectrum effects”), but the extent of
this varied by device.
Interpretation: The estimates of sensitivity and specificity can be used to adjust for test error rates when using
these devices to estimate the prevalence of antibody. If tests were used to determine whether an individual
has SARS-CoV-2 antibodies, in an example scenario in which 20% of individuals have antibodies we estimate
around 5% of positive results on the most specific device would be false positives.
Funding: Public Health England.







V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Tests for SARS-CoV-2 antibodies are used for population serosur-
veillance [1,2] and could in future be used for post-vaccination seroe-
pidemiology. Given evidence that antibodies are associated with
reduced risk of COVID-19 disease [3-7], antibody tests might also
have a role in individual risk assessment [8], pending improved
understanding of the mechanisms and longevity of immunity. Bothuses require understanding of test sensitivity and specificity: these
can be used to adjust seroprevalence estimates for test errors [9],
while any test used for individual risk assessment would need to be
shown to be sufficiently accurate, in particular, highly specific
[10,11].
A number of laboratory-based immunoassays and lateral flow
immunoassays (LFIAs) are now available, which detect IgG and/or
IgM responses to the spike or nucleoprotein antigens [12-14]. Fol-
lowing infection with SARS-CoV-2, most individuals generate
antibodies against both of these antigens [15]. Existing efficacious
recombinant vaccines contain the spike antigen [16], therefore
Research in Context
Evidence before this study
We searched for evidence on the accuracy of the four devices
compared in this study: OrientGene COVID IgG/IgM Rapid Test
Cassette, SureScreen COVID-19 Rapid Test Cassette, Biomerica
COVID-19 IgG/IgM Rapid Test and the UK Rapid Test Con-
sortium’s AbC-19TM Rapid Test. We searched Ovid MEDLINE
(In-Process & Other Non-Indexed Citations and Daily), PubMed,
MedRxiv/BioRxiv and Google Scholar from January 2020 to 16th
January 2021. Search terms included device names AND
((SARS-CoV-2) OR (covid)). Of 303 records assessed, data were
extracted from 24 studies: 18 reporting on the accuracy of the
OrientGene device, 7 SureScreen, 2 AbC-19TM and 1 Biomerica.
Only three studies compared the accuracy of two or more of
the four devices. With the exception of our previous report on
the accuracy of the AbC-19TM device, which the current manu-
script builds upon, sample size ranged from 7 to 684. For
details, see Supplementary Materials (Figure S1, Tables S1, S2).
The largest study compared OrientGene, SureScreen and
Biomerica. SureScreen was estimated to have the highest speci-
ficity (99.8%, 95% CI 98.9 to 100%) and OrientGene the highest
sensitivity (92.6%), but with uncertainty about the latter result
due to small sample sizes. The other two comparative studies
were small (n = 65, n = 67) and therefore provide very uncertain
results.
We previously observed spectrum effects for the AbC-19TM
device, such that sensitivity is upwardly biased if estimated
only from PCR-confirmed cases. The vast majority of previous
studies estimated sensitivity in this way.
Added value of this study
We performed a large scale (n = 4,842), head-to-head labora-
tory-based evaluation and comparison of four lateral flow devi-
ces, which were selected for evaluation by the UK Department
of Health and Social Care’s New Tests Advisory Group, on the
basis of a survey of test and performance data available. We
evaluated the accuracy of diagnosis based on both IgG and IgM
bands, and the IgG band alone. We found a clear trade-off
between sensitivity and specificity across devices, with the
SureScreen and AbC-19TM devices being more specific and Ori-
entGene and Biomerica more sensitive. Based on analysis of
1,995 pre-pandemic blood samples, we are 99% confident that
SureScreen (IgG band reading) has the highest specificity of the
four devices (98.9%, 95% CI 98.3, 99.3%).
By including individuals without PCR confirmation, and
exploring the relationship between laboratory immunoassay
antibody index and LFIA positivity, we were able to explore
spectrum effects. We found evidence that all four devices have
reduced sensitivity at lower antibody indices. However, the
extent of this varies by device and appears to be less for other
devices than for AbC-19.
Our estimates of sensitivity and specificity are likely to be
higher than would be observed in real use of these devices, as
they were based on majority readings of three trained labora-
tory personnel.
Implications of all the available evidence
When used in epidemiological studies of antibody prevalence,
the estimates of sensitivity and specificity provided in this
study can be used to adjust for test errors. Increased precision
in error rates will translate to increased precision in seropreva-
lence estimates. If lateral flow devices were used for individual
risk assessment, devices with maximum specificity would be
preferable. However, if, for example, 20% of the tested popula-
tion had antibodies, we estimate that around 1 in 20 positive
results on the most specific device would be incorrect.
2 H.E. Jones et al. / EBioMedicine 68 (2021) 103414vaccinated individuals generate only a response to this. LFIAs are
small devices which produce results rapidly, without the need for
a laboratory, and therefore have the potential to be employed at
scale.
A Cochrane review found 38 studies evaluating LFIAs for SARS-
CoV-2 antibodies already by late April 2020. However, results
from most studies were judged to be at high risk of bias, and
very few studies directly compared multiple devices [14]. Where
direct comparisons have been performed, they have shown that
accuracy of LFIAs varies widely across devices [13,17-20]. A key
limitation of most studies is that sensitivity has been estimated
only from individuals who previously had a positive PCR test. In
a recent evaluation of one LFIA, the UK Rapid Test Consortium’s
“AbC-19TM Rapid Test” [21] (AbC-19 hereafter), we found evi-
dence that this can over-estimate sensitivity [21]. We attributed
this to PCR-confirmed cases tending to be more severe  particu-
larly early in the pandemic, when access to testing was very lim-
ited. Since more severe disease is associated with increased
antibody concentrations [22-24], which may be easier to detect,
estimates of test sensitivity based on previously PCR-confirmed
cases only are susceptible to “spectrum bias” [25,26].
In this paper, we present a head-to-head comparison of the accu-
racy of AbC-19 and three other LFIAs, based on a large (n = 4,842)
number of blood samples. The three additional devices were Orient-
Gene “COVID IgG/IgM Rapid Test Cassette”, SureScreen “COVID-19
Rapid Test Cassette”, and Biomerica “COVID-19 IgG/IgM Rapid Test”,
hereafter referred to as OrientGene, SureScreen and Biomerica for
brevity.
Methods
We analysed blood samples from 2,847 key workers participating
in the EDSAB-HOME study and 1,995 pre-pandemic blood donors
from the COMPARE study [27], in a laboratory setting. All samples
were from distinct individuals. We evaluated each device using two
approaches. First (Approach 1), we compared LFIA results with the
known previous infection status of pre-pandemic blood donors
(“known negatives”) and the 268 EDSAB-HOME participants who
reported previous PCR positivity (“known positives”). Second
(Approach 2), we compared LFIA results with results on two sensitive
laboratory immunoassays in EDSAB-HOME participants. Both
approaches were pre-specified in our protocol (available at http://
www.isrctn.com/ISRCTN56609224).
We have previously reported accuracy of the AbC-19 device based
on the same sample set and overall approaches: these results are
reproduced here for comparative purposes [21]. Following this previ-
ous work, and in particular due to the spectrum effects observed [21]
we anticipated the estimates of sensitivity based on comparison with
a laboratory immunoassay (Approach 2) but estimates of specificity
based on pre-pandemic sera (Approach 1) to be the least susceptible
to bias.
Lateral flow immunoassays
Devices (Table S3) were selected by the UK Department of Health
and Social Care’s New Tests Advisory Group, on the basis of a survey
of test and performance data available. AbC-19, OrientGene and Sure-
Screen devices contain SARS-CoV-2 Spike protein, or domains from it,
while Biomerica contains Nucleoprotein. All four devices give qualita-
tive positive or negative results. AbC-19 detects IgG only, while the
H.E. Jones et al. / EBioMedicine 68 (2021) 103414 3other three devices contain separate bands representing detection of
IgG and IgM. We report results for these by two different scoring
strategies: (i) “one band”, in which we considered a result to be posi-
tive only if the IgG band was positive; and (ii) “two band”, in which
we considered results to be positive if either band was positive. In
statistical analysis, these two readings were treated as separate
“tests”, such that our comparison was of seven tests in total. By defi-
nition, the “two band” reading of each device has sensitivity greater
than or equal to, but specificity less than or equal to, the “one band”
reading.Fig. 1. Study floStudy participants
The two sets of study participants have been described in full pre-
viously [21]. A flow diagram is provided (Fig. 1).
EDSAB-HOME (ISRCTN56609224) was a prospective study
designed to assess the accuracy of LFIAs in key workers in England
[24]. The research protocol is available at http://www.isrctn.com/
ISRCTN56609224. Participants were convenience samples, recruited
through their workplaces in three recruitment streams. Individuals
in Streams A (fire and police officers: n = 1,147) and B (healthcarew diagram
4 H.E. Jones et al. / EBioMedicine 68 (2021) 103414workers: n = 1,546) were recruited without regard to previous SARS-
CoV-2 infection status. Stream C (n = 154) consisted of additional
healthcare workers who were recruited based on self-reported previ-
ous PCR positivity. Symptom history was not part of the eligibility cri-
teria. During June 2020, all participants (n = 2,847) completed an
online questionnaire and had a venous blood sample taken at a study
clinic.
Sample size considerations, eligibility criteria, the recruitment
process and demographic characteristics (Table S4) are described in
the Supplementary Materials. Detailed information on participants
from the study questionnaire (including symptom history, testing
history and household exposure) is provided elsewhere [24]. In addi-
tion to the Stream C individuals, some Stream A/B individuals
(n = 114) also self-reported previous PCR positivity. All self-reported
PCR results were later validated by comparison with national labora-
tory records. We refer to the total (n = 268) individuals with a previ-
ous PCR positive result as “known positives” and to the remaining
n = 2,579 EDSAB-HOME participants as “individuals with unknown
previous infection status” at clinic visit. Twelve of 268 known posi-
tives reported having experienced no symptoms. Of the known posi-
tives reporting symptoms, the median (interquartile range) number
of days between symptom onset and study clinic was 63 (52 to 75).
COMPARE (ISRCTN90871183) was a 2016-2017 blood donor
cohort study in England [27]. We performed stratified random sam-
pling by age, sex and region to select 2,000 participants, of whom
1,995 had samples available for analysis. We refer to these samples
as “known negatives”.
Laboratory protocol
All tests were performed by experienced laboratory staff at PHE
Colindale, London. All EDSAB-HOME samples were first tested with
two laboratory immunoassays: Roche Elecsys, which measures total
(including IgG and IgM) antibodies against the Nucleoprotein, and
EuroImmun Anti-SARS-CoV-2 ELISA assay, which measures IgG anti-
bodies against the S protein S1 domain. Any immunoassay failing for
technical reasons was repeated.
Lateral flow devices were stored in a temperature controlled room
(thresholds 16-30°C, actuals from continuous monitoring system 19-
20°C). Laboratory staff reading the LFIAs received on-site training
from Abingdon Health (the manufacturers of the AbC-19 device),
SureScreen and Biomerica. Laboratory staff discussed the evaluation,
including use of the LFIA device, with OrientGene on a call. The man-
ufacturers’ instructions for use were followed, with plasma being
pipetted into the devices, followed by the chase buffer supplied with
the kits.
The first 350 COMPARE samples were interspersed randomly
among EDSAB-HOME samples, with the remaining 1,650 COMPARE
samples being analysed later. Each device was independently read by
three members of staff. Readers were blind to demographic or clinical
information on participants and to results on any previous assays.
Readers scored LFIA test bands using the WHO scoring system for
subjectively read assays: 0 (“negative”), 1 (“very weak but definitely
reactive”), 2 (“medium to strong reactivity”) or 7 (“invalid”) [28]. As
this scoring system does not clearly state how to categorise “weak”
bands, our readers used a score of 1 for what they considered to be
either “weak” or “very weak”. The majority score was taken as the
consensus reading. For assessment of test sensitivity and specificity,
scores of 1 and 2 were grouped as “positive”. If any band of a device
was assigned a consensus score of 7 (invalid), the sample was re-
tested and the re-test results taken as primary. We report numbers
and proportions of invalid bands, and the total number and propor-
tion of all devices with at least one invalid band.
We re-tested samples when LFIAs made apparent errors, on the
following basis: for all four devices, we re-tested EDSAB-HOME sam-
ples if the result differed from the immunoassay composite referencestandard of “positive on either Roche Elecsys or EuroImmun, versus
negative on both”. For three of the four devices, we also re-tested all
COMPARE samples that incorrectly tested positive. For Biomerica,
due to a lack of devices and a high observed false positive rate, only
false positives in the first batch of 350 samples were re-tested. Any
re-test results are reported as secondary.
Two checks were made before pipetting to ensure that samples
were in the correct position. Once results were available, an initial
check was made to ensure that no obvious mistakes had been made
by readers on the laboratory scoring sheet (i.e. that scoring was for
the correct sample). Data were then manually entered into a spread-
sheet for each test run and every result checked against the primary
data (laboratory scoring sheet). Results were transferred from each
test run spreadsheet to the main results sheet, and checked for cor-
rect alignment.
Estimation of sensitivity, specificity, positive and negative predictive
values
Approach 1
We estimated LFIA accuracy through comparison of results with
the known previous SARS-CoV-2 infection status of individuals. Spec-
ificity was estimated from all 1,995 “known negative” samples. The
association of false positivity with age, sex and ethnicity was also
explored. We estimated sensitivity from the 268 “known positive”
EDSAB-HOME samples. Numbers of false negatives are also reported
by time since symptom onset and separately for asymptomatic indi-
viduals.
Approach 2
We estimated LFIA accuracy through comparison with results on
the Roche Elecsys laboratory immunoassay in EDSAB-HOME sam-
ples. This was selected as the primary laboratory reference standard
on the basis that it was the assay available to us that had the highest
published accuracy for detection of recent SARS-CoV-2 infection at
the time of sample collection, as per our protocol. We used the manu-
facturer recommended positivity threshold of 1.0. At this threshold,
the assay has been estimated to have sensitivity of 97.2% (95% CI
95.4, 98.4%) and specificity of 99.8% (99.3, 100%) to previous infection
[12]. As sensitivity analyses, we also report accuracy estimates based
on comparison with EuroImmun and a composite reference standard
of “positive on either laboratory assay versus negative on both”. We
treated EuroImmun results as positive if they were greater than or
equal to the manufacturer “borderline” threshold of 0.8 [24].
In Approach 2, estimates of sensitivity were calculated separately
for known positives and individuals with unknown previous infec-
tion status, to assess for potential spectrum bias [21]. Specificity was
estimated from reference standard negative individuals among the
“unknown previous infection status” population. As EDSAB-HOME
Streams A and B comprise a “one gate” population [21,29], we also
report Approach 2 results from all EDSAB-HOME streams A and B
participants combined, regardless of previous PCR positivity.
Positive and negative predictive values: We estimated the positive
and negative predictive value (PPV and NPV) for example scenarios
of a 10%, 20% and 30% pre-test probability. To calculate these, we
used estimates of specificity based on pre-pandemic sera (Approach
1) and sensitivity based on comparison with Roche Elecsys in indi-
viduals with unknown previous infection status (Approach 2). As
noted above, we anticipated that these estimates of the respective
parameters would be the least susceptible to bias.
Statistical analysis
Statistical analysis was performed in R4.0.3 and Stata 15. Sensitiv-
ity and specificity were estimated by observed proportions based on
each reference standard, with 95% CIs computed using Wilson’s
H.E. Jones et al. / EBioMedicine 68 (2021) 103414 5method. Logistic regressions with age, sex and ethnicity as covariates
were used to explore potential associations with false positivity. To
further explore potential associations with age, we also fitted frac-
tional polynomials and plotted the best fitting functional form for
each test.
In comparing the sensitivity and specificity of the seven “tests”,
we used generalised estimating equations (GEE) to account for condi-
tional correlations among results [30]. For example, in Approach 1 we
fitted separate GEE regressions, with test as a covariate, to the
“known positives” and to the “known negatives”. We used indepen-
dence working covariance matrices [30].
We obtained 95% uncertainty intervals (UIs) around PPVs, NPVs,
differences in sensitivity and differences in specificity using Monte
Carlo simulation. This is a commonly used approach for propagating
uncertainty in functions of parameters, used frequently for example
in decision modeling [31]. We sampled one million iterations from a
multivariate normal distribution (using R function “mvnorm”) for
each set of GEE regression coefficients, using the parameter estimates
and robust variance-covariance matrix. We calculated each function
of parameters of interest (e.g. the PPV at 20% prevalence) at each iter-
ation. We report the median value across iterations as the parameter
estimate and 2.5th and 97.5th percentiles as 95% uncertainty intervals.
We also present ranks (from 1 to 7) for each set of sensitivity, speci-
ficity and PPV estimates. These were similarly computed at each iter-
ation of the Monte Carlo simulations, and summarised by medians,
2.5th and 95.5th percentiles across simulations [32]. We further report
the proportion of simulations for which each test was ranked first, i.e.
the probability the test is the "best" with regard to each measure.
Assessment of spectrum effects in test sensitivity
Within the Approach 2 analysis of Roche Elecsys positives, we
report the absolute difference between sensitivity estimated from
PCR-confirmed cases and sensitivity estimated from individuals with
unknown previous infection status, with 95% UI.
Among individuals who were positive on Roche Elecsys, we also
examined the relationship between the amount of antibody present
and the likelihood of lateral flow test positivity. We categorised anti-
Nucleoprotein (Roche Elecsys) and, separately, anti-S1 (EuroIm-
mun) antibody indices into bins containing similar number of sam-
ples and calculated the observed sensitivity (i.e. proportion of
positive results) with 95% CI for each LFIA in each bin.
To aid visual assessment of the relationship between antibody
index and sensitivity, we also plotted exploratory dose-response
curves. The shape of fitted curve was selected using the Akaike infor-
mation criteria, using the drc package in R [33].
Ethics statement
The EDSAB-HOME study was approved by the NHS Research
Ethics Committee (Health Research Authority, IRAS 284980, date 2nd
June 2020) and the PHE Research Ethics and Governance Group
(REGG, NR0198, date 21st May 2020). All participants gave written
informed consent. Ethical approval for use of samples from the COM-
PARE study is covered by approval from NHS Research Ethics Com-
mittee Cambridge East (ref 15/EE/0335, date 18th December 2015).
Role of the funding source
The study was commissioned by the UK Government’s Depart-
ment of Health and Social Care (DHSC), and was funded and imple-
mented by Public Health England, supported by the NIHR Clinical
Research Network Portfolio. The DHSC had no role in the study
design, data collection, analysis, interpretation of results, writing of
the manuscript, or the decision to publish.Results
Main results
Figs. 2 and 3 show results from Approach 1 and from the
Approach 2 analysis of individuals with unknown previous infection
status at clinic visit, which are mutually exclusive and exhaustive
subsets of the 4,842 samples. Also shown are results from the
Approach 2 sensitivity analyses with alternative reference standards.
Estimated differences between the sensitivity and specificity of tests,
with 95% UIs, are shown in Tables S5 and S6.
Both approaches show a clear trade-off between sensitivity and
specificity, with SureScreen 1 band and AbC-19 having higher specif-
icities but lowest sensitivities, while OrientGene and Biomerica have
higher sensitivities but lower specificities.
From Approach 1, SureScreen 1 band is estimated to have higher
specificity but lower sensitivity than AbC-19, whereas the two tests
appeared comparable (although with all point estimates marginally
favouring SureScreen) from Approach 2. Resulting from this, we esti-
mate the one band reading of the SureScreen device to have the high-
est PPV.
Approach 1: comparison with known previous infection status
Approach 1 estimates are shown in Tables 1 (specificity) and 2
(sensitivity).
SureScreen 1 band reading was estimated to have 98.9% specific-
ity (95% CI 98.3, 99.3%), with high certainty (99%) of this being the
highest. This is 1.0% (95% UI 0.2, 1.8%) higher than the specificity of
AbC-19 (Table S6), which was ranked 2nd (95% UI 2nd, 4th). There was
no strong evidence of any association between false positivity and
age for any device (Table S7) although there was some indication
that Biomerica 1 band specificity might decline in older adults (Figure
S2). With the exception of an apparent association of false positivity
of the AbC-19 device with sex, which we have reported previously
[21], there was no indication of specificity varying by sex or ethnicity
(Table S8).
SureScreen 1 band was, however, estimated to have the lowest
sensitivity when this was estimated from PCR-confirmed cases only
(Table 2: 88.8%, 95% CI 84.5, 92.0%), 3.7% (95% UI 0.5, 7.1%) lower than
AbC-19 (Table S5).
Approach 2: comparison with laboratory immunoassay results in
EDSAB-HOME samples
Among the 268 “known positives”, nine were negative on Roche
Elecsys. Removing these from the denominator slightly increased
point estimates of sensitivity (Table 3), but had no notable impact on
rankings. Among the 2,579 individuals with unknown previous infec-
tion status, 354 were positive on Roche Elecsys. Point estimates of
sensitivity were lower for all seven tests in this population than
among known positives (see below). In this population, there was
evidence that both the OrientGene and Biomerica devices have
higher sensitivity than SureScreen or AbC-19 (Table S5). There was
no evidence of a difference between the sensitivity of SureScreen and
AbC-19 (absolute difference in favour of SureScreen = 0.8%, 95% UI
-2.2, 3.9%). Increases in sensitivity in the 2 band versus 1 band read-
ing of OrientGene and Biomerica devices were minimal.
Based on the 2,225 individuals with unknown previous infection
status who were negative on Roche Elecsys, specificity estimates
were very similar to those from Approach 1 for SureScreen and Bio-
merica, but around 1% higher for AbC-19 and OrientGene (Table 3).
The ranking of devices was consistent across the two approaches, but
the observed difference in specificity between SureScreen and AbC-
19 was much reduced in Approach 2 (difference = 0.1%, 95% UI -0.4 to
0.6%, Table S6).
Figs. 2, 3 and Tables S9, S10 show results from sensitivity analyses
on the 2,579 samples from individuals with unknown previous
Fig. 2. Sensitivity and specificity of lateral flow devices, with 95% confidence intervals. Four sets of estimates are shown: (i) Approach 1, i.e. specificity from analysis of known nega-
tives and sensitivity from known positives (sample size: n = 1,995 for specificity, n = 268 for sensitivity); (ii) Approach 2 analysis of individuals with unknown previous infection sta-
tus (“unknowns”), calculated against Roche Elecsys reference standard (sample size: n = 2,225 for specificity, n = 354 for sensitivity); (iii) Approach 2 sensitivity analysis: analysis of
unknowns compared with alternative EuroImmun reference standard (n = 2,233 for specificity, n = 346 for sensitivity); (iv) Approach 2 sensitivity analysis: analysis of unknowns
compared with alternative composite reference standard (CRS) of positive on either Roche Elecsys or EuroImmun versus negative on both (n = 2,207 for specificity, n = 372 for sen-
sitivity.
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dard, estimates of specificity were robust, while sensitivity appeared
slightly higher for AbC-19, OrientGene and SureScreen, but slightly
lower for Biomerica, although with overlapping CIs. All devices were
estimated to have slightly lower sensitivity when evaluated against
the composite reference standard. OrientGene was ranked highest
for sensitivity across all three immunoassay reference standards, but
with Biomerica appearing as a close contender when evaluated
against Roche Elecsys.
Table S11 shows sensitivity and specificity estimated from all
EDSAB-HOME Streams A and B (“one gate” study), based on compari-
son with each of the three immunoassay reference standards. Rank-
ings of devices were quite robust to inclusion of PCR-confirmed
cases.
Re-test results are shown in Table S12.Positive and negative predictive values
Based on the sets of estimates that we consider least susceptible
to bias (see Methods), we are 99% confident that SureScreen 1 band
reading has the highest PPV. This ranking does not depend on pre-
test probability (Table 4, Figure S4). At a pre-test probability of 20%,
we estimate SureScreen 1 band reading to have a PPV of 95.1% (95%
UI 92.6, 96.8%), such that we would expect approximately one in
twenty positive results to be incorrect.
OrientGene and Biomerica have the highest ranking NPVs. There
is very little difference between the NPVs for the one or two band
readings of these devices (Table 4).Spectrum effects
For all seven tests, point estimates of sensitivity were lower
among individuals with unknown previous infection status who
were positive on Roche Elecsys than among PCR-confirmed cases,
with strong statistical evidence of a difference for all tests except Ori-
entGene (Table 3). The greatest observed difference was for AbC-19.
Fig. 4 shows that all devices were more sensitive at higher anti-
body concentrations. This effect was most marked in the devices
with lower sensitivity, particularly AbC-19. All LFIAs had high sensi-
tivity at the highest anti-S IgG concentrations, but at lower concen-
trations many lateral flow tests were falsely negative (Figure S3,
Tables S13, S14).
Usability issues
Very few bands or devices produced invalid readings (Table S15).
Laboratory assessors reported that SureScreen bands were intense,
well defined and easy to read, and that OrientGene bands were also
easy to read. For Biomerica, some gradients and streaking in band for-
mation were observed, which led to devices taking slightly longer to
read. As we have reported previously, AbC-19 bands were often weak
visually [21].
All devices showed some variability in reading across three asses-
sors. Concordance was highest for the SureScreen IgG band: there
were no discrepancies in the reading of this for 98.7% (98.3, 98.9%) of
devices (Table S16). Positive OrientGene, Biomerica and SureScreen
IgG bands all tended to be stronger than AbC-19 bands: for example,
across the 613 EDSAB-HOME samples that were positive on Roche
Fig. 3. Sensitivity and specificity of lateral flow devices, with 95% confidence intervals, plotted in Receiver Operator Characteristic space. Four sets of estimates are shown: (i)
Approach 1, i.e. specificity from analysis of known negatives and sensitivity from known positives (sample size: n = 1,995 for specificity, n = 268 for sensitivity); (ii) Approach 2 anal-
ysis of individuals with unknown previous infection status (“unknowns”), calculated against Roche Elecsys reference standard (sample size: n = 2,225 for specificity, n = 354 for
sensitivity); (iii) Approach 2 sensitivity analysis: analysis of unknowns compared with alternative EuroImmun reference standard (n = 2,233 for specificity, n = 346 for sensitivity);
(iv) Approach 2 sensitivity analysis: analysis of unknowns compared with alternative composite reference standard (CRS) of positive on either Roche Elecsys or EuroImmun versus
negative on both (n = 2,207 for specificity, n = 372 for sensitivity). NB SureScreen 2 band overlays Orient Gene 1 band in the first panel.
H.E. Jones et al. / EBioMedicine 68 (2021) 103414 7Elecsys, 76%, 69% and 79% showed “medium to strong reactivity”
respectively, compared with 44% of AbC-19 devices (Table S17). Con-
cordance was lower for reading of IgM than IgG bands. IgM bands,
when read as positive, were also often weak.
Discussion
We found evidence that SureScreen (when reading the IgG band
only) and AbC-19 have higher specificities than OrientGene and Bio-
merica, but the latter have higher sensitivities. We can confidently
conclude that SureScreen 1 band reading has ~99% specificity, since
this estimate was robust across two large discrete samples sets. In
contrast, estimates of the specificity of AbC-19 and OrientGene varied
slightly across Approaches 1 and 2. As Approach 2 denominators are
subject to some misclassification error, we consider the estimates of
specificity based on pre-pandemic samples to be most reliable.
The sensitivities of OrientGene and Biomerica appeared compara-
ble based on a reference standard of Roche Elecsys (anti-N) immu-
noassay, whereas OrientGene appeared to have higher sensitivity
when an alternative (anti-S) reference standard was used. This differ-
ence is not surprising since Biomerica also measures anti-N response
whereas OrientGene (and the other two devices studied) measures
anti-S response. For all four devices, there was some evidence of
lower sensitivity to detect lower concentrations of antibody. This
spectrum effect appeared strongest for the AbC-19 test and weakestfor OrientGene. Due to spectrum effects, we consider Approach 2
estimates of sensitivity to be the most realistic.
Notably, none of the four devices met the UK Medicines and
Health products Regulatory Agency’s requirement of sensitivity
>98% for the use case of individual level risk assessment [11], even in
our least conservative analytical scenario, which we expect to over-
estimate sensitivity. On the other hand, the basis for this criterion is
unclear, as we would expect high specificity to be the key consider-
ation for this potential use case.
Major strengths of this work include its size and performance of
all LFIAs on an identical sample set. This design is optimal for com-
paring test accuracy [34]. Inclusion of laboratory immunoassay posi-
tive cases without PCR confirmation is an additional key strength
over most previous studies in this field (see Research in Context panel
and Table S2): this allowed assessment and quantification of spec-
trum effects. Antibody test sensitivity may have been over-estimated
by studies that have quantified this from previously PCR-confirmed
cases alone, particularly if blood samples were taken at a point when
access to PCR testing was very limited.
A limitation of our study is that tests were conducted in a labora-
tory setting, with the majority reading across three expert readers
being taken as the result. For devices with discrepancies between
readers, the accuracy of a single reader can be expected to lower [21].
Accuracy may be lower still if devices were read by individuals at
home with less or no training, and may differ if device reading
Table 1
Specificity of lateral flow devices: Approach 1 (known negatives). Estimates based on analysis of 1,995 pre-pandemic samples. CI = confidence interval, UI = uncertainty inter-
val based on percentiles from Monte Carlo simulation, TNs = true negatives, FPs = false positives, “Probability best” = the proportion of Monte Carlo simulations in which the
test had the highest specificity. Note: these AbC-19TM results have been published previously (21) and are reproduced here for comparative purposes.
Lateral flow immunoassay
AbC-19TM Orient Gene 1 band Orient Gene 2 bands SureScreen 1 band SureScreen 2 bands Biomerica 1 band Biomerica 2 bands
TNs 1,953 1,934 1,911 1,973 1,935 1,942 1,835

































Probability best 0.01 0.00 0.00 0.99 0.00 0.00 0.00
Table 2
Sensitivity of lateral flow devices: Approach 1 (known positives). Estimates based on analysis of 268 individuals self-reporting previous PCR confirmed infection. CI = confidence
interval, UI = uncertainty interval based on percentiles from Monte Carlo simulation, TPs = true positives, FNs = false negatives, “Probability best” = the proportion of Monte Carlo
simulations in which the test had the highest sensitivity. Note: these AbC-19TM results have been published previously (21) and are reproduced here for comparative purposes.
Lateral flow immunoassay
AbC-19TM Orient Gene 1 band Orient Gene 2 bands SureScreen 1 band SureScreen 2 bands Biomerica 1 band Biomerica 2 bands
TPs 248 252 252 238 252 253 255
FNs 20 16 16 30 16 15 13
Sensitivity
(95% CI)



















0.01 0.08 0.08 0.00 0.14 0.04 0.64
False negatives by days since between symptom onset and blood sample:
Asymptomatic (n=12) 5 3 3 5 4 4 4
8-21 days (n=5) 0 0 0 0 0 0 0
22-35 days (n=20) 1 1 1 2 1 1 1
36-70 days (n=142) 6 4 4 12 5 2 1
71 days (n=89) 8 8 8 11 6 8 7
Table 3
Sensitivity and specificity of lateral flow devices: Approach 2. Comparison with Roche Elecsys immunoassay in EDSAB-HOME samples, stratified by previous PCR positivity.
CI = confidence interval, UI = uncertainty interval based on percentiles from Monte Carlo simulation, “Probability best” = the proportion of Monte Carlo simulations in which
the test had the highest sensitivity or specificity. Note: the AbC-19TM results have been published previously (21) and are reproduced here for comparative purposes.
AbC-19TM Orient Gene 1 band Orient Gene 2 bands SureScreen 1 band SureScreen 2 bands Biomerica 1 band Biomerica 2 bands
Analysis of 268 PCR-confirmed cases
Reference standard of Roche Elecsys: 259 positive
False negatives 15 12 12 23 10 8 6














Ranked sensitivity (95% UI) 6 (3, 7) 4 (2, 6) 4 (2, 6) 7 (6, 7) 3 (1, 6) 2 (1, 6) 1 (1, 5)
Probability best sensitivity 0.00 0.01 0.01 0.00 0.14 0.05 0.79
Analysis of 2,579 individuals with unknown previous infection status
Reference standard of Roche Elecsys: 354 positive and 2,225 negative
False negatives 54 28 27 51 36 29 28














Ranked sensitivity (95% UI) 7 (6, 7) 2 (1, 4) 1 (1, 4) 6 (6, 7) 5 (3, 5) 4 (1, 5) 3 (1, 4)
Probability best sensitivity 0.00 0.07 0.50 0.00 0.00 0.06 0.36
False positives 24 47 62 22 59 66 176














Ranked specificity (95% UI) 2 (1, 2) 3 (3, 4) 5 (4, 6) 1 (1, 2) 4 (3, 6) 6 (3, 6) 7 (7, 7)
Probability best specificity 0.37 0.00 0.00 0.63 0.00 0.00 0.00
Absolute difference in sensitiv-
ity: known positives vs indi-
viduals with unknown
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Fig. 4. Sensitivity of lateral flow devices, with 95% confidence intervals, by antibody index (categorised into groups of approximately equal size), among n = 613 EDSAB-HOME par-
ticipants who were positive on Roche Elecsys . Top panel: sensitivity by anti-Nucleoprotein antibody (Roche Elecsys); Bottom Panel: sensitivity by anti-Spike IgG (EuroImmun).
Lines show exploratory dose-response curves based on aWeibull function. Red lines: lateral flow test contains nucleoprotein; Blue lines: lateral flow test contains spike proteins.
Table 4
Positive predictive value (PPV) and negative predictive value (NPV), with 95% uncertainty intervals (UIs), for example scenarios of 10%, 20% and 30% pre-test probability.
“Probability best” = the proportion of Monte Carlo simulations in which the test had the highest PPV or NPV. Specificity was estimated from 1,995 pre-pandemic samples
(Table 1) and sensitivity from 354 Roche Elecsys positives with unknown previous infection status at clinic visit (Table 3).
AbC-19TM Orient Gene 1 band Orient Gene 2 bands SureScreen 1 band SureScreen 2 bands Biomerica 1 band Biomerica 2 bands
Positive predictive value (PPV)
PPV at 10% pre-test
probability (95% UI)












































Ranked PPV (UI) 2 (2, 4) 4 (2, 5) 6 (6, 6) 1 (1, 1) 4 (2, 5) 3 (2, 5) 7 (7, 7)
Probability best PPV 0.01 0.00 0.00 0.99 0.00 0.00 0.00
Negative predictive value (NPV)
















































Ranked NPV (UI) 7 (6, 7) 2 (1, 4) 2 (1, 4) 6 (6, 7) 5 (3, 5) 3 (1, 5) 3 (1, 5)
Probability best NPV 0.00 0.13 0.48 0.00 0.00 0.29 0.10
H.E. Jones et al. / EBioMedicine 68 (2021) 103414 9
10 H.E. Jones et al. / EBioMedicine 68 (2021) 103414technologies were used. Variation by reader type seems particularly
likely for the devices that our laboratory assessors found more diffi-
cult to read, due to weak bands or gradients and streaking in band
formation. SureScreen IgG band, followed by OrientGene IgG band,
had the highest concordance across readers, who also reported these
bands to be easy to read.
An ongoing difficulty in this field is the ambiguity as to whether
the true parameters of interest are sensitivity and specificity to previ-
ous infection, to presence of particular antibodies, or to “immunity”.
Our estimates are best interpreted as sensitivity and specificity to
“recent” SARS-CoV-2 infection (Approach 1) or presence of an anti-
body response (Approach 2). These can be expected to correlate very
highly since most individuals seroconvert [15] and both the anti-S
and anti-N antibody response are highly specific to SARS-CoV-2 [12].
Although we believe that, due to spectrum effects, our estimates of
sensitivity based on a reference standard of Roche Elecsys are more
reliable than those based on previous PCR confirmation, we note that
this assay may itself make some errors, and that evaluation against
this assay may tend to favour LFIAs measuring anti-N responses. We
explored this with sensitivity analyses using two alternative refer-
ence standards.
Although there is strong evidence that presence of antibody
response correlates with reduced risk [3,4], our estimates should not
be directly interpreted as sensitivity and specificity to detect “immu-
nity” or to detect “any” previous infection (given declining antibody
response over time). Further, our study describes test accuracy fol-
lowing natural infection, not after vaccination. Estimates of sensitiv-
ity would require further validation in vaccinated populations if the
tests were to be used for post-vaccination monitoring. Notably, anti-
gen choice precludes both Biomerica and Roche Elecsys from this
use case. An additional limitation of our analyses is that we did not
quantify the accuracy of tests used in sequence, e.g. check positive
results on Test A with a confirmatory Test B [35]. Finally, we esti-
mated device accuracy in key workers in the UK and we note that
accuracy may not be generalisable to other populations.
If these devices are used for seroprevalence estimation, our esti-
mates of LFIA accuracy can be used to adjust for test errors [9]. The
“one gate” estimates of sensitivity would likely be the most appropri-
ate for this. For the alternative potential use case of individual risk
assessment (pending improved understanding of immunity), it
would be desirable to use the most specific test or that with the high-
est PPV, which we estimate to be SureScreen 1 band reading, fol-
lowed by AbC-19. At a 20% seroprevalence, we estimate that around
1 in 20 SureScreen IgG positive readings would be a false positive.
Confirmatory testing, possibly with a second LFIA, would be an
option, although requires evaluation.
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